Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence
Sponsor: Weill Cornell Medical College in Qatar
Trial Details
| Condition | Cardio Vascular Disease, Acute Coronary Syndromes (ACS), Type 2 Diabetes, Pre Diabetes, Artifical Intelligence |
| Status | Not_yet_recruiting |
| Participants | 10,000 |
| Est. Completion | 16 July 2030 |
| Last Updated | 21 Apr 2026 |
Primary Outcome
For ACS patients; For Heart Failure patients
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: \- 1. Age ≥ 18 2. Qatari and Arab patients 3. Patients admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF). 4\. Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or Pre-diabetes: 5.7 ≥ HbA1C ≤ 6.4 Exclusion Criteria: * 1\. Non-Qatari or non-Arab patients 2. Non-diabetic: HbA₁c \< 5.7% 3. This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service